Vincerx Pharma to present three posters at AACR

Vincerx Pharma “announced it will present three posters at the American Association for Cancer Research, AACR, Annual Meeting 2024, taking place in San Diego, CA, from April 5 – 10, 2024. Vincerx will also share clinical data for VIP236 at the conference.” CEO Ahmed Hamdy stated: “We are extremely pleased to highlight the continued development of our next-generation VersAptx(TM) bioconjugation platform in these three abstract/poster presentations. In addition to the preclinical results of our VersAptx platform, our SMDC poster will also present, for the first time, early clinical results for VIP236. To date, 20 patients with relapsed/refractory advanced or metastatic solid tumors have been treated with two different dosing schedules of VIP236. The poster will summarize preliminary safety, efficacy, and pharmacokinetic results from this first-in-human, dose-escalation study.”